RT Journal Article
SR Electronic
T1 Heterologous immunization with inactivated vaccine followed by mRNA booster elicits strong humoral and cellular immune responses against the SARS-CoV-2 Omicron variant
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.04.22268755
DO 10.1101/2022.01.04.22268755
A1 Zuo, Fanglei
A1 Abolhassani, Hassan
A1 Du, Likun
A1 Piralla, Antonio
A1 Bertoglio, Federico
A1 de Campos-Mata, Leire
A1 Wan, Hui
A1 Schubert, Maren
A1 Wang, Yating
A1 Sun, Rui
A1 Cassaniti, Irene
A1 Vlachiotis, Stelios
A1 Kumagai-Braesch, Makiko
A1 Andréll, Juni
A1 Zhang, Zhaoxia
A1 Xue, Yintong
A1 Wenzel, Esther Veronika
A1 Calzolai, Luigi
A1 Varani, Luca
A1 Rezaei, Nima
A1 Chavoshzadeh, Zahra
A1 Baldanti, Fausto
A1 Hust, Michael
A1 Hammarström, Lennart
A1 Marcotte, Harold
A1 Pan-Hammarström, Qiang
YR 2022
UL http://medrxiv.org/content/early/2022/01/06/2022.01.04.22268755.abstract
AB Background There has been an unprecedented global effort to produce safe and effective vaccines against SARS-CoV-2. However, production challenges, supply shortages and unequal global reach, together with an increased number of breakthrough infections due to waning of immunity and the emergence of new variants of concern (VOC), have prolonged the pandemic. To boost the immune response, several heterologous vaccination regimes have been tested and have shown increased antibody responses compared to homologous vaccination. Here we evaluated the effect of mRNA vaccine booster on immunogenicity in individuals who had been vaccinated with two doses of inactivated vaccines.Methods The levels of specific antibodies against the receptor-binding domain (RBD) of the spike protein from wild-type virus and the Beta, Delta and Omicron variants were measured in healthy individuals who had received two doses of homologous inactivated (BBIBP-CorV or CoronoVac) or mRNA (BNT162b2 or mRNA-1273) vaccines, and in donors who were given an mRNA vaccine boost after two doses of either vaccine. Pre-vaccinated healthy donors, or individuals who had been infected and subsequently received the mRNA vaccine were also included as controls. In addition, specific memory B and T cell responses were measured in a subset of samples.Results A booster dose of an mRNA vaccine significantly increased the level of specific antibodies that bind to the RBD domain of the wild-type (6-fold) and VOCs including Delta (8-fold) and Omicron (14-fold), in individuals who had previously received two doses of inactivated vaccines. The level of specific antibodies in the heterologous vaccination group was furthermore similar to that in individuals receiving a third dose of homologous mRNA vaccines or boosted with mRNA vaccine after natural infection. Moreover, this heterologous vaccination regime significantly enhanced the specific memory B and T cell responses.Conclusions Heterologous prime-boost immunization with inactivated vaccine followed by an mRNA vaccine boost markedly increased the levels of specific antibodies and B and T cell responses and may thus increase protection against emerging SARS-CoV-2 variants including Omicron.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by The European Union's Horizon 2020 research and innovation program (ATAC, 101003650), the Center for Innovative Medicine at the Karolinska Institutet, the Swedish Research Council and the Knut and Alice Wallenberg Foundation (KAW).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethics committees in institutional review board (IRB) of Stockholm, Technische Universitat Braunschweig and the Tehran University of Medical Sciences.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors